Amyloid Clinical Trials

5 recruiting

Amyloid Trials at a Glance

166 actively recruiting trials for amyloid are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Phase 2 with 31 trials, with the heaviest enrollment activity in Boston, New York, and London. Lead sponsors running amyloid studies include Fondazione IRCCS Policlinico San Matteo di Pavia, Alnylam Pharmaceuticals, and Mayo Clinic.

Treatments under study

About Amyloid Clinical Trials

Looking for clinical trials for Amyloid? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Amyloid trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Amyloid clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 166 trials

Recruiting

The Eplontersen Pregnancy and Lactation Outcomes Study

Transthyretin Amyloidosis
AstraZeneca10 enrolled1 locationNCT07205666
Recruiting
Phase 4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Transthyretin Amyloid Cardiomyopathy
Bayer50 enrolled10 locationsNCT07298044
Recruiting
Phase 1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Relapsed/Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.9 enrolled9 locationsNCT07250269
Recruiting
Phase 3

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

Cardiac Amyloidosis
Brigham and Women's Hospital20 enrolled1 locationNCT07560306
Recruiting

A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany

ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Pfizer1 enrolled1 locationNCT07494656
Recruiting
Phase 2

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals200 enrolled57 locationsNCT06393712
Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals2,000 enrolled4 locationsNCT07358078
Recruiting
Phase 1Phase 2

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled19 locationsNCT06292780
Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

PolyneuropathyHereditary Transthyretin-mediated (hATTR) Amyloidosis
Alnylam Pharmaceuticals10 enrolled7 locationsNCT05040373
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled289 locationsNCT07207811
Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

ATTR Amyloidosis
AstraZeneca52,121 enrolled26 locationsNCT06355934
Recruiting
Phase 2

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

AL Amyloidosis
European Myeloma Network B.V.30 enrolled10 locationsNCT06649695
Recruiting
Phase 3

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals125 enrolled4 locationsNCT07223203
Recruiting
Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled207 locationsNCT07052903
Recruiting

Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

Cardiac Amyloidosis
Gérond'if637 enrolled36 locationsNCT06427304
Recruiting

A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation

CardiomyopathyCardiac AmyloidosisIschemic Heart Disease
Mayo Clinic10,040,000 enrolled1 locationNCT07308704
Recruiting

A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)

AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia400 enrolled6 locationsNCT06205953
Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple MyelomaAL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia760 enrolled4 locationsNCT06383143
Recruiting

A Registry of AL Amyloidosis (ReAL)

AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia5,000 enrolled1 locationNCT04839003
Recruiting

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

AmyloidosisAmyloidosis CardiacATTR Amyloidosis Wild Type
Paolo Milani200 enrolled1 locationNCT06251778